文献速递肝病

REEF-2 II期试验中一例HBV诱导的肝衰竭:对HBV「治愈」有限疗程策略的启示

A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'.
PubMed 文献 · J Hepatol · 2022-03-28

核苷(酸)类似物长期抑制HBV病毒复制但难以实现功能性治愈。本文报告一例在REEF-2临床试验方案中停用核苷(酸)类似物后不久发生严重乙型肝炎再激活的病例,尽管给予最佳支持治疗并迅速重新启用替诺福韦,患者仍发展为亚急性肝衰竭,需紧急原位肝移植。该病例凸显有限疗程治疗的潜在风险,并强调需改进生物标志物驱动的策略及重新评估研究方案。

要点

  • REEF-2试验中一例患者停用核苷(酸)类似物后发生严重乙型肝炎再激活。
  • 尽管最佳支持治疗并迅速重新启用替诺福韦,仍发展为亚急性肝衰竭需紧急原位肝移植。
  • 该病例提示有限疗程治疗存在潜在风险,需改进生物标志物驱动策略并重新评估研究方案。

核心结论

  • 在追求HBV治愈的过程中,本病例凸显有限疗程治疗的潜在风险,并强调需改进生物标志物驱动的策略和重新评估研究方案。

研究设计与样本

  • 本文为REEF-2 II期临床试验中一例HBV再激活导致肝衰竭的病例报告。

主要发现

  • 患者在临床试验方案内停用核苷(酸)类似物后不久发生严重乙型肝炎再激活。
  • 尽管给予最佳支持治疗并迅速重新启用替诺福韦,患者仍发展为亚急性肝衰竭,需紧急原位肝移植。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nucleoside analogues are the mainstay of treatment for patients with chronic HBV infection but have no direct effect on covalently closed circular DNA. Long-term HBV viral suppression is now routine, but the desirable endpoint of functional cure is rarely achieved. Newer therapies, targeting other aspects of the replicative life cycle of HBV, present opportunities to deliver finite therapy and HBV 'cure'. This is an area of keen focus for the HBV community. We describe a severe case of hepatitis B reactivation, occurring shortly after the withdrawal of a nucleoside analogue within the protocol of a clinical trial (REEF-2). Despite best supportive care and prompt re-introduction of tenofovir, the patient developed subacute liver failure, requiring emergency orthotopic liver transplantation. As we strive to achieve HBV cure, this case highlights the potential risks of finite therapy and highlights the need for improved biomarker-driven strategies and re-evaluation of study protocols.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Agarwal K, Lok J, Carey I, et al. A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'. J Hepatol. 2022. PMID: 35358614. doi:10.1016/j.jhep.2022.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。